Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean 3.2.1 001 5?
Displaying drugs 6376 - 6400 of 10285 in total

Tianeptine

Tianeptine is a drug used primarily in the treatment of major depressive disorder and has been studied in the treatment of irritable bowel syndrome (IBS) . Structurally, it is classified as a tricyclic antidepressant (TCA), however, it possesses different pharmacological properties than typical tricyclic antidepressants . Tianeptine was discovered and...
Investigational
Matched Iupac: … -hexaen-2-yl}amino)heptanoic acid ... 7-({6-chloro-10-methyl-9,9-dioxo-9lambda6-thia-10-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3(8),4,6,11,13 …
Matched Salts cas: … 30123-17-2 …

1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol

Experimental
Matched Name: … 1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol …
Matched Iupac: … 1-[(2-amino-7H-purin-6-yl)oxy]-3-methylbutan-2-one …

2-(1H-pyrazol-3-yl)-1H-benzimidazole

Experimental
Matched Name: … 2-(1H-pyrazol-3-yl)-1H-benzimidazole …
Matched Iupac: … 2-(1H-pyrazol-3-yl)-1H-1,3-benzodiazole …

N-(3-AMINOPROPYL)-2-NITROBENZENAMINE

Experimental
Matched Name: … N-(3-AMINOPROPYL)-2-NITROBENZENAMINE …
Matched Iupac: … N1-(2-nitrophenyl)propane-1,3-diamine …

VLTS-589

VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.
Investigational

NP-50301

NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals. It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. The majority of sufferers of DES are...
Investigational

SNX-5422

SNX-5422 is a synthetic, novel, small molecule Hsp90 Inhibitor. As an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers.
Investigational
Matched Iupac: … (1r,4r)-4-({2-carbamoyl-5-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl] ... phenyl}amino)cyclohexyl 2-aminoacetate …
Matched Categories: … Heterocyclic Compounds, 2-Ring …

KRN-5500

KRN-5500 is under investigation in clinical trial NCT00002923 (KRN5500 in Treating Patients With Metastatic Solid Tumors).
Investigational
Matched Iupac: … 3-yl]carbamoyl}methyl)tetradeca-2,4-dienamide ... (2E,4E)-N-({[(2R,3R,4R,5R,6S)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxy-6-[(9H-purin-6-yl)amino]oxan- …
Matched Categories: … Heterocyclic Compounds, 2-Ring …

V590

The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®[A226818, L30573, L30578]. By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose . Other features of...
Investigational

AZD-5069

Investigational
Matched Iupac: … N-(2-{[(2,3-difluorophenyl)methyl]sulfanyl}-6-{[(2R,3S)-3,4-dihydroxybutan-2-yl]oxy}pyrimidin-4-yl)azetidine …

KITE-585

KITE-585 is an autologous, fully-human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy. It is being investigated in the treatment of multiple myeloma.
Investigational

ABBV-514

ABBV-514 is in development for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in combination with a PD-1 inhibitor.
Investigational

[2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone

Experimental
Matched Name: … [2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone …
Matched Iupac: … 3-benzoyl-6-(2,6-difluorobenzoyl)imidazo[1,2-a]pyridin-2-amine …

4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile

Experimental
Matched Name: … 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile …
Matched Iupac: … 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile …

3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE

Experimental
Matched Name: … 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE …
Matched Iupac: … 3-(1H-1,3-benzodiazol-2-yl)-1H-indazole …

3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE

Experimental
Matched Name: … 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE …
Matched Iupac: … 3-[(naphthalen-1-yl)methoxy]pyridin-2-amine …

1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol

Experimental
Matched Name: … 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol …
Matched Iupac: … (1R)-1-{4-[(9aS)-octahydro-1H-pyrido[1,2-a]pyrazin-2-yl]phenyl}-2-phenyl-1,2,3,4-tetrahydroisoquinolin …

(1S,7S,8S,8AR)-1,2,3,7,8,8A-HEXAHYDRO-7-METHYL-8-[2-[(2R,4R)-TETRAHYDRO-4-HY DROXY-6-OXO-2H-PYRAN-2-YL]ETHYL]-1-NAPHTHALENOL

Experimental
Matched Name: … (1S,7S,8S,8AR)-1,2,3,7,8,8A-HEXAHYDRO-7-METHYL-8-[2-[(2R,4R)-TETRAHYDRO-4-HY DROXY-6-OXO-2H-PYRAN-2-YL …
Matched Iupac: … -2-one ... (4R,6S)-6-{2-[(1S,2S,8S,8aR)-8-hydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]ethyl}-4-hydroxyoxan …

Telacebec

Investigational
Matched Synonyms: … Imidazo(1,2-a)pyridine-3-carboxamide, 6-chloro-2-ethyl-n-((4-(4-(4-(trifluoromethoxy)phenyl)-1-piperidinyl ... -3-carboxamide ... 6-chloro-2-ethyl-n-((4-(4-(4-(trifluoromethoxy)phenyl)-1-piperdinyl)phenyl)methyl)-imidazo(1,2-a)pyridine …
Matched Iupac: … -3-carboxamide ... 6-chloro-2-ethyl-N-[(4-{4-[4-(trifluoromethoxy)phenyl]piperidin-1-yl}phenyl)methyl]imidazo[1,2-a]pyridine …

6-AMINO-3,7-DIHYDRO-IMIDAZO[4,5-G]QUINAZOLIN-8-ONE

Experimental

1-Methylhistidine

Experimental
Matched Synonyms: … (2S)-2-amino-3-(1-methyl-1H-imidazol-4-yl)propanoic acid …
Matched Iupac: … (2S)-2-amino-3-(1-methyl-1H-imidazol-4-yl)propanoic acid …

Homogentisic acid

Experimental
Matched Iupac: … 2-(2,5-dihydroxyphenyl)acetic acid …

Dociparstat sodium

Investigational

GO-203-2C

GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Investigational
Matched Iupac: … 2-{[(2R)-5-carbamimidamido-2-{[(2R)-5-carbamimidamido-2-{[(2R)-5-carbamimidamido-2-{[(2R)-5-carbamimidamido ... )-5-carbamimidamido-2-{[(2R)-5-carbamimidamido-2-{[(2R)-5-carbamimidamido-2-{[(2R)-5-carbamimidamido- ... methylidene}amino)-1-hydroxypentylidene]amino}-1-hydroxypentylidene]amino}-1-hydroxyhexylidene]amino}-3- ... (2R)-2-{[(2R)-6-amino-2-{[(2R)-5-carbamimidamido-2-{[(2R)-5-carbamimidamido-2-({[(4S,7R,10S)-10-{[(2R ... -2-{[(2R)-5-carbamimidamido-1-hydroxy-2-[(1-hydroxyethylidene)amino]pentylidene]amino}-1-hydroxypentylidene …

4-[[(2S)-2-[[(2S)-3-Carboxy-2-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]butyl-(diaminomethylidene)azanium

Experimental
Matched Name: … 4-[[(2S)-2-[[(2S)-3-Carboxy-2-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]butyl-(diaminomethylidene …
Matched Iupac: … {4-[(2S)-2-[(2S)-3-carboxy-2-hydroxypropanamido]-4-methylpentanamido]butyl}(diaminomethylidene)azanium …
Displaying drugs 6376 - 6400 of 10285 in total